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Background: Lung cancer is the major cause of cancer-related deaths and many cases of Non Small Cell Lung
Cancer (NSCLC), a common type of lung cancer, have frequent genetic/oncogenic activation of EGFR, KRAS, PIK3CA,
BRAF, and others that drive tumor growth. Some patients though initially respond, but later develop resistance
to erlotinib/gefitinib with no option except for cytotoxic therapy. Therefore, development of novel targeted
therapeutics is imperative to provide improved survival benefit for NSCLC patients. The mTOR cell survival pathway
is activated in naïve, or in response to targeted therapies in NSCLC.
Methods: We have discovered P7170, a small molecule inhibitor of mTORC1/mTORC2/ALK1 and investigated its
antitumor efficacy using various in vitro and in vivo models of human NSCLC.
Results: P7170 inhibited the phosphorylation of AKT, S6 and 4EBP1 (substrates for mTORC2 and mTORC1) levels by
80-100% and growth of NSCLC cells. P7170 inhibited anchorage-independent colony formation of NSCLC patient
tumor–derived cells subsistent of disease sub-types. The compound also induced apoptosis in NSCLC cell lines. P7170
at a well-tolerated daily dose of 20 mg/kg significantly inhibited the growth of NSCLC xenografts independent of
different mutations (EGFR, KRAS, or PIK3CA) or sensitivity to erlotinib. Pharmacokinetic-pharmacodynamic (PK-PD)
analysis showed sub-micro molar tumor concentrations along with mTORC1/C2 inhibition.
Conclusions: Our results provide evidence of antitumor activity of P7170 in the erlotinib –sensitive and –insensitive
models of NSCLC.
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Lung cancer remains the leading cause of cancer related
deaths worldwide. Eighty-five percent of the lung cancer
cases are presented as Non-Small Cell Lung Cancers
(NSCLC) in contrast to fifteen percent of Small Cell
Lung Cancers (SCLC), and typically seventy-five percent
of NSCLC new cases are being diagnosed at late
advanced disease stage (ACS, Surveillance Research,
2013; [1]). Current research suggests that the importance
of several molecular signaling pathways in Non-Small* Correspondence: veena_828@yahoo.com
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unless otherwise stated.Cell Lung Cancer (NSCLC) cells that promote tumor
growth. These include, but are not limited to activating
mutations or amplification of EGFR, KRAS, PIK3CA,
BRAF, and EML4-ALK gene rearrangements and loss of
PTEN [2-4].
The frequencies of activating mutations of EGFR and/
or KRAS in NSCLC varied in different studies (8–60%)
depending on the patient selection biases [5-7]. Recently,
in a large and unselected cohort prospective screening
of newly diagnosed 552 NSCLC patients, the EGFR
mutation rate was found to be only 4.9% [8]. Despite an
improved PFS (progression free survival) with EGFR-
TKI (tyrosine kinase inhibitor) that effectively targetstral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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remained controversial [9,10]. These findings suggest a
possible role of other molecular pathways in the NSCLC
disease progression. A retrospective study of patients
showed that KRAS mutation with or without EGFR copy
number alteration could predict chances of NSCLC dis-
ease progression [11]. Blocking RAS-RAF-MEK-ERK cell
growth pathway that channelizes signals from upstream
EGFR, KRAS, and BRAF [12-14] has been shown to be
important in treating NSCLC. In addition, constitutive
activation of AKT has emerged as a mechanism of cell
survival and/or resistance to chemotherapy and radiation
in NSCLC [15]. Utilization of ErbB-3 signaling in response
to gefitinib in gefitinib-sensitive cells and IGFIR signaling
in gefitinib-resistant cells was shown as a compensatory
mechanisms that result in the activation of phosphoino-
sitide 3-kinase (PI3K) in EGFR wild type NSCLC cells
[16,17]. Also, cooperative up regulation of PI3K and
mammalian Target Of Rapamycin (mTOR) pathways in
NSCLC patient specimens with or no EGFR mutations
suggested the importance of PI3K-mTOR signaling in
NSCLC [18-20]. Additionally, suppression of PI3K-mTOR
pathway has shown to be effective in inhibiting the growth
of KRAS mutant NSCLC tumors in a mouse model [21].
Hyper activation of mTOR signaling frequently occurs in
nearly 70% of patient tumors and because mTOR regulate
eukaryotic cellular functions such as cell growth, cell
survival, metabolism, response to stress, translation, and
transcription through multiple pathways [22], several
mTOR inhibitors are being discovered and evaluated for
cancer therapy. It is now understood that both mTORC1
and mTORC2 activity is essential for growth of a subset of
tumors by activating 4EBP1/ribosomal S6 and AKT re-
spectively, hence an inhibitor for the same remain needed.
Therefore, we developed an mTOR pathway inhibitor
P7170 that showed potent inhibitory activity on mTORC1,
mTORC2, and ALK1. [A separate manuscript under
revision in the journal, Molecular Cancer Therapeutics;
AACR 2012 conference posters: Agarwal VR et al., Can
Res, 2012, 72(8 Supplement): Abstract no 3742 and
3759]. In this report we provide evidence for its efficacy
in patient tumor-derived lung cancer cells in vitro and
in mouse models of erlotinib-sensitive and -insensitive
NSCLC cell line-derived xenografts. The chemical structure
of P7170 is included in the patent # WO-2012007926A1.
Results
P7170 inhibited mTOR signaling
We evaluated the activity of P7170 in cell based assays.
The phosphorylation of AKT (S473) (substrate of mTORC2)
[23], S6 (indirect substrate of mTORC1), and 4EBP1
(substrate of mTORC1) were nearly completely inhibited
(100%) in H460 NSCLC cells upon treatment with 50 nM
P7170. In the same experiment, phosphorylation of ERK,the effector of RAF-MEK-ERK pathway was marginally
decreased (10%) (Figure 1A). The kinase activities of up-
stream PI3K alpha and mTOR were inhibited by P7170
(IC50 = 2.2 and 4.4 nM, respectively) but potent biochem-
ical activity of PI3K did not translate in intact cells most
likely because of feedback mechanism of mTOR inhibition.
P7170 is a weak PI3K inhibitor (a separate manuscript
submitted). In an immunofluorescence assay, P7170 treat-
ment caused a consistent and marked decrease in the
phosphorylation of S6 with a concentration-dependent
suppression of p4EBP1 in H460 cells (Figure 1B, Additional
file 1: Figure S1). Longer incubation time with P7170
resulted in an enhanced inhibition of pS6 and p4EBP1
(Additional file 1: Figure S1). The effect of P7170 on cell
growth was evaluated in three different NSCLC cell lines,
where a dose-dependent inhibition was observed. The
IC50 of P7170 in EGFR over expressing A431 (EGFR wild
type) cells was 10 nM compared to 5 and 7 nM in KRAS
mutant A549 and H460 cell lines, respectively. In general,
P7170 showed nano molar IC50 concentrations in the
growth of various NSCLC cell lines as opposed to micro
molar IC50 of erlotinib (Figure 1C).
P7170 inhibited the clonogenic potential of patient tumor
derived cancer cells
Tumor specimens used in this study were histologically
derived from three sub-types e.g., adenocarcinoma (FA),
squamous cell carcinoma (FE), or large cell carcinoma
(FL) where, the tumor cells derived from human xenografts
were designated with a prefix ‘LX’ (Table 1). Although the
mutation status of EGFR or other key genes in these pa-
tient tumor-derived cells is unknown, the status of KRAS,
PIK3CA, or PTEN was mostly wild type (Table 1). To
examine the effect of P7170 on the clonogenic activity,
tumor cells obtained from 13 different lung cancer patient
biopsies were treated with P7170 (0.01 nM–1 μM)
followed by monitoring their growth in soft-agar. The
concentration that resulted in the 50% attenuation of col-
ony formation (IC50) of P7170 was computed as described
in Table 1 and Additional file 2: Figure S2. The IC50 values
for P7170 were in the broad range of 3 to 300 nM inde-
pendent of either the genetic status of KRAS, PIK3CA,
PTEN or the tumor sub-types (Table 1).
P7170 caused apoptosis and STAT3 inhibition in cancer
cell lines
To further understand the mechanism of cell growth
inhibition, H460 cells were treated with P7170 for 24 h
and analyzed by flow cytometry for propidium positive
dead cells. A significant increase in dead cells upon
treatment with P7170 was observed at 10 nM compared
to untreated control (p < 0.05; Figure 2A). In the Annexin
V-propidium iodide apoptosis assay, we found that treat-
ment with 300 nM P7170 resulted in a 35% loss of cell
Figure 1 P7170 inhibited PI3K/mTOR signaling and the growth of erlotinib-resistant NSCLC cell lines. (A) Exponentially growing H460
cells were seeded in petridishes (2 × 106 cells/dish) and after cell attachment overnight, cells were serum starved for 14-16 h. Cells were then
treated for 1 h with P7170 followed by 0.5 h incubation in the presence of 20% fetal bovine serum. Cells were trypsinized and lysed before
electrophoresis of cellular extracts for western blot analyses of proteins of interest. (B) Quantification of pS6 and p4EBP1 protein levels in H460
cells after acquisition and analyses of immunofluorescence signals in the Cellomics Array scan platform. H460 cells were seeded in 96-well plates
and treated with 0.1 or 1 μM of P7170 for 16 h; drug-containing media was removed and the cells were fixed and stained with antibodies to
phosphorylated form of human S6 and 4EBP1 proteins and secondary antibodies conjugated to DyLight 549. Statistical significance values are as
follows: *p < 0.05, **p < 0.01, ***p < 0.001. (C) IC50 of erlotinib or P7170 in various NSCLC cell lines after 48 h of treatment.
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cells in early apoptosis indicating the onset of cell death
(Figure 2B; Additional file 3: Figure S3). The onset of
apoptosis correlated with cell growth inhibition at similar
concentrations (100 – 300 nM) and at the same incuba-
tion time of 24 h (Figure 2A). To ascertain whether apop-
totic response by P7170 involves DNA damage or elicited
DNA damage-repair response, PARP cleavage, a widely
used marker for measuring DNA-damage repair response
was examined. In a separate experiment, treatment of
H460 cells with an increasing concentration of P7170 was
found to induce PARP cleavage (Figure 2C).
Since P7170 also inhibited JAK2 kinase activity (IC50:
39 nM, manuscript submitted), we evaluated STAT3 ac-
tivation, a target downstream of JAK2 because similar to
PI3K pathway, STAT-family members are activated upon
phosphorylation (at different Serine/Tyrosine residues)
by cytokines and growth factors. Using a cell basedSTAT3-reporter assay, P7170 demonstrated a marked in-
hibition of transcriptional activation of STAT3 in HeLa
cells (p < 0.01) with minimal (18%) cytotoxicity (IC50:
4.7nM, Figure 2D). Also, in an immunofluorescence
assay in A549 NSCLC cells, there was a prominent de-
crease in the nuclear staining for phosphorylated STAT3
(Y705) after treatment with 0.1–1 μM P7170 (Figure 2E).
In vivo anti-tumor efficacy of P7170 in mice bearing
NSCLC xenografts
In order to understand the antitumor efficacy of P7170
in erlotinib-sensitive and insensitive in vivo models, sub-
cutaneous xenografts of NSCLC, using H1975, H1650,
or H460 cell lines were established. Although H1650
and H1975 cell lines are equally responsive to erlotinib
in vitro, literature [24,25] suggests that H1975 xenografts
are erlotinib-resistant. Treatment with P7170 resulted in
a significant growth inhibition (70% TGI, p < 0.001,
Table 1 P7170 inhibits the growth of NSCLC patient-derived cancer cells
Tumor designation Model # Histology Kras PIK3CA PTEN IC50 (nM)
LXFA 1012 adenocarcinoma wt wt wt 45
LXFA 1584 adenocarcinoma NA NA NA 2
LXFA 586 adenocarcinoma wt wt wt 9
LXFA 629 adenocarcinoma wt wt wt 5.5
LXFA 677 adenocarcinoma wt wt wt 300
LXFA 737 adenocarcinoma wt wt wt 300
LXFA 749 adenocarcinoma wt wt wt 17
LXFE 1422 Squamous cell carcinoma wt wt wt 8.5
LXFE 470 Squamous cell carcinoma wt E545K heterozygous wt 50
LXFE 646 Squamous cell carcinoma wt wt wt 100
LXFL 1674 Large cell G12C homozygous wt wt 30
LXFL 430 Large cell wt wt wt 3
LXFL 529 Large cell wt wt wt 50
Various patient tumor xenograft-derived NSCLC cells treated with P7170 at log concentrations (range: 0.01 nM – 1 μM) followed by growth in soft-agar to evaluate
colony formation. Description of patient’s tumor histology sub-type, mutation status, and IC50 of P7170 in these tumor xenograft-derived cells by soft-agar colony
formation is shown.
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sensitive cells [EGFR del E748-A750 (activating mutation);
KRAS mutant; PIK3CA wild type] at 5 mg/kg, a dose
much lower than its MTD. However, the same dose of
P7170 was not very effective in mice bearing erlotinib-
insensitive H1975 [EGFR T790M, L858R; KRAS wild type;
PIK3CA wild type] xenografts, but treatment with a15
mg/kg dose resulted in a significant tumor growth
inhibition (92% TGI, p < 0.001, Table 2). Interestingly,
P7170 was efficacious (88% TGI at 20 mg/kg; 66% TGI at
10 mg/kg with p < 0.001, Table 2 and Figure 3A) in
another model of erlotinib -insensitive H460 (EGFR wild
type; KRAS mutant; PIK3CA mutant) xenografted ani-
mals. P7170 administration was well tolerated at doses up
to 20 mg in different xenograft models (Additional file 4:
Figure S4). These results provide evidence for the efficacy
of P7170 in erlotinib-sensitive, and –insensitive NSCLC
irrespective of known genetic mutations in these cells.
Pharmacokinetic-pharmacodynamic correlation of P7170 in
human H460 NSCLC xenograft model
H460 xenograft model was chosen for this study. Tumor
bearing mice were treated with different doses of P7170.
Administration of P7170 at a 20 mg/kg dose resulted in
88% tumor growth inhibition (Figure 3A) confirming the
results of a previous experiment (Table 2). Tumor growth
inhibition with 5 and 10 mg/kg doses was significant com-
pared to the vehicle (~53 and 66% respectively, p < 0.05)
but did not differ much between the doses. In the efficacy
study (Figure 3A); plasma and tumor samples collected at
1, 4, 8, or 24 h post P7170-last dose were analyzed to
determine the concentrations of P7170 by LC-MS. The re-
sults of this experiment indicate a dose dependent increasein P7170 concentrations in the tumors based on area under
the curve (AUC) (*p < 0.05 between two doses for plasma
or tumor P7170 concentrations independently; §p < 0.05 is
the significance when concentrations of P7170 in the
plasma and tumor were compared; Figure 3B). Also, P7170
concentrations were 2.7-fold higher in tumor versus plasma
in 20 mg/kg group.
In a separate PK-PD study, H460 xenograft-bearing mice
were treated with P7170 (1, 5, 10, or 20 mg/kg/day) con-
secutively for 3 days. Plasma and tumor samples were col-
lected at 1, 4, 8, and 24 h after the administration of the
last dose for PK-PD-analyses. Based on the time to achieve
Cmax, plasma and tumor concentrations of P7170 were
pooled from two time points (1 and 4 h) in each group
(Figure 3B). Tumor to plasma concentrations revealed
a preferential accumulation of P7170 in the tumor
than plasma in a dose-dependent manner (3 – 11-fold)
(Figure 3B). To ascertain the pharmacodynamic effect
of P7170 in tumor xenografts, western blotting of key
proteins in the PI3K-Akt-mTOR pathway in tissue
extracts was performed, and the representative protein
blots derived from the samples collected during 1-8 h
post P7170-last-dose are shown (Figure 3C). AKT phos-
phorylation (S473) the direct substrate of mTORC2
was found to be strongly inhibited in response to 10 or
20 mg/kg treatment. Also, the phosphorylation of ribo-
somal S6 (S235/236) and 4EBP1 (T37/46), targets down-
stream of mTOR were inhibited by 5-20 mg/kg doses
(Figure 3C). For the PK-PD-analyses, the normalized indi-
vidual protein band intensities (pAKT, pS6, or p4EBP1)
were plotted against P7170 concentrations in respective
tumor samples. PK-PD analyses were carried out based on
Inhibitory Emax models (Additional file 5: Table S1) using
Table 2 P7170 decreased growth of NSCLC cell
line-derived tumor xenografts
Percent tumor growth inhibition in NSCLC-derived xenografts
P7170 (p.o., QD) H1650 H1975 H460
5 mg/kg 70% (p < 0.001) 45% (p < 0.01) 53% (p < 0.001)
15 mg/kg 92% (p < 0.001) 66% (p < 0.001)
20 mg/kg 88% (p < 0.0001)
Duration of
treatment
15 days 13 days 11 days
Tumor volume at the beginning of treatment ~ 100 mm3
Nude mice bearing xenografts of human NSCLC cell lines H1650, H1975, or
H460 were treated with P7170 at indicated doses for 10 – 15 days (p.o., QD).
All mice maintained body weight with a loss not more than 10%.
Figure 2 P7170 induced apoptosis and decreased STAT3 activity in NSCLC cells. (A) Cell growth inhibition of exponentially growing H460
NSCLC cells by P7170. (B) Annexin V and propidium iodide positive cells analyzed by flow cytometry after 16 h of treatment. (C) H460 cells were
seeded in 90 mm Petri dishes (1 × 106 cells/ plate). The cells were serum starved for 16 h. Fresh medium was added to the plates and treated with P7170
(0.1, 0.3, and1 μM) for 24 h; total cellular proteins were processed for western blotting for cleaved PARP; (D) Inhibition of STAT3 activity performed using
Panomics STAT3 luciferase kit, corresponding cell toxicity at same concentrations of P7170 was determined by PI-based assay (plotted on the secondary
axis on right side of the panel). (E) Immunofluorescence staining for STAT3 phosphorylation in A549 NSCLC cells: pSTAT3 (red) and nucleus (blue).
See Methods for details.
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correlation between the level of tumor biomarkers (pAKT,
pS6, and p4EBP1) and plasma and tumor concentrations
of P7170. A trend showing a decrease in pS6 levels with
increasing tumor and plasma P7170 on day 3, indicates
target pathway engagement (Figure 3D). No correlations
were observed for pAKT and p4EBP1 (Additional file 6:
Figure S5). Additional details for PD model and parameter
estimates are presented in Additional file 5: Table S1.Statistics
Results are presented as mean ± standard deviation. Stat-
istical significance was determined using the two-way
ANOVA with Turkey’s post hoc test. Data with p < 0.05
were considered significant. Statistical analysis was done
using GraphPad Prism, version 5.0c.
Figure 3 Anti-tumor efficacy of P7170 correlated with tumor pharmacokinetic and pharmacodynamic parameters. (A) Tumor volume (mm3)
of H460 xenografts in SCID mice was measured in P7170 treatment groups twice weekly. (B) For pharmacodynamic studies, P7170 was administered
into tumor bearing mice once daily consecutively for 3 days. Plasma and tumors samples were collected at 1, 4, 8, 24 h post-P7170-last dose (minimum
3 mice per time point) for estimating P7170 concentrations by LC-MS/MS. P7170 concentrations for each dose (1, 5, 10, or 20 mg/kg) were calculated
based on the AUC (area under curve) constructed using concentrations at 1, 4, 8, 24 h post-P7170-last dose. Statistical significance: *p < 0.05 (C)
Representative protein western blots showing response to the treatment in the experiment (B). (D) In the same experiment as in (B), part of tumor
tissues was processed for western blotting analyses of proteins using specific antibodies; protein band intensities were normalized to respective loading
controls. The band intensities of pS6 were plotted against the absolute plasma or tumor P7170 concentrations. The correlations of pS6 (S235/236)
levels to plasma or tumor P7170 concentrations were performed using the non-compartmental analysis tool of WinNonlin Professional version 6.1:
Predicted curve represents the trend in protein level derived from each tumors sample (closed circles) with respect to tumor concentrations of P7170.
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In cancer, majority of growth factor receptor protein
tyrosine kinases such as EGFR, HER2/3, FGFR, PDGFR,
IGFR were found to be hyper activated. The important
downstream pathways that are instrumental in regulating
cell survival include, PI3K/mTOR and RAS-ERK. Many
PI3K-AKT inhibitors have not produced the expected
responses in patients with advanced cancers at tolerated
doses. Benefit from AKT inhibition is limited due to
mTORC2-mediated reactivation of PI3K-AKT signaling
[23]. As mTOR is frequently hyper activated in human
tumors and because the activity of both mTORC1 and
mTORC2 complexes is essential for growth of a subset of
tumors we aimed to develop an inhibitor for both these
complexes.
We describe here the antitumor efficacy of an agent
P7170 attributed to inhibition of mTORC1/mTORC2/
ALK1, and JAK-STAT3 signaling in NSCLC. We showthat treatment with P7170 results in a marked reduction
in the survival of NSCLC cells with different mutations in
EGFR, KRAS, PIK3CA, or PTEN and inhibition of tumor
growth in vivo. Supported by its pharmacodynamic effects
(inhibition of phosphorylation of mTOR pathway proteins
such as AKT, ribosomal S6, and 4EBP1) development of
P7170 provides an attractive opportunity as a treatment
option for NSCLC.
Consistent with reports suggesting a critical importance
of mTOR pathway for the clonogenic cell growth [26], we
found P7170 to inhibit colony formation of various
patient-derived NSCLC cell lines in the soft-agar assay.
Inhibition of mTOR signaling contributed to increased
cellular apoptosis (PARP cleavage and Annexin V posi-
tive cells) with concomitant decrease in the growth of
H460 cells. The decreased cell growth by P7170 could
have resulted in inability of cells to colonize. An IC50
concentration of P7170 (10 nM) where 50% of cells did
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may be involved mediating cell death. To delineate this,
we found studies reporting a persistent activation of
STAT3 (pSTAT3) in nearly 50% of lung adenocarcin-
omas [27]. It is known that JAK2 directly regulate
STAT3 activation [28], and since P7170 is known to
have activity against the JAK2 kinase, it was hypothe-
sized that P7170 may inhibit STAT3 activation. As ex-
pected, P7170 inhibited STAT3 activity in a luciferase
expression system in HeLa cells. In an immunofluores-
cence assay, P7170 has also inhibited STAT3 phosphor-
ylation (Y705) in situ in A549 NSCLC cells. In
understanding the functional effect of these results, a
study showed that inhibition of STAT3 was responsible
for NSCLC tumor growth suppression [29] suggesting
that inhibition of JAK2-STAT3 could be a mechanism
for cellular apoptosis in P7170 treated cells.
We have demonstrated the in vivo antitumor efficacy of
P7170 in xenograft models of different erlotinib-sensitive,
and –resistant NSCLC cell lines at tolerated doses, and
particularly, in xenografts derived from EGFR T790M,
L858R erlotinib-resistant cells. The results of the present
PK/PD study show mTORC1 and mTORC2 target
engagement with a negative correlation between tumor
volume and plasma/tumor P7170 concentrations. With
the patient treatment in perspective, second generation
EGFR TKI or combination with mTOR inhibitor for
NSCLC patients with EGFR T790M mutation [30] could
potentially become options. Although therapeutic options
for NSCLC patients with KRAS mutation is lacking, new
approaches in the clinical testing such as dual MEK and
mTOR inhibition or cytotoxic drugs [31] are being
evaluated. Therefore, targeting of mTOR cell survival/
growth pathways in subjects with erlotinib –sensitive and
–insensitive NSCLC might be beneficial. In summary,
P7170 showed a target engagement, resulted in tumor cell
killing leading to tumor growth inhibition in vivo.
Conclusions
Taken together, our results demonstrate that P7170 has
NSCLC cell killing activity via inhibition of mTORC1/
mTORC2 and JAK2-STAT3 signaling. This activity resulted
in tumor growth inhibition as a single agent in the
in vivo xenograft models. Therefore, we propose that
P7170 could produce benefit in patients with erlotinib-
sensitive, and –insensitive NSCLC.
Methods
Cell lines and culture
A549, H358, H1975, H1650, and H460 cell lines were
purchased from ATCC and maintained in RPMI1640,
supplemented with 10% heat inactivated FBS (Gibco).
STAT3 Reporter HeLa Stable Cell Line (stably trans-
fected with Luciferase gene under the control of STAT3promoter) was purchased from Panomics, USA and was
maintained in DMEM supplemented with 10% FBS under
hygromycin B (Sigma H3274) selection condition. Experi-
mental culture conditions for patient tumor derived cells
are given below in methods.
Cell growth inhibition assay
Propidium iodide assay
Exponentially growing cells were plated in 96-well plate
24 h before treatment with P7170. After 48 h of incuba-
tion plates were washed with 1× PBS followed by addition
of PI-containing PBS (7 μg/ml) and storage at -80°C. After
thawing the plate PI fluorescence was measured in
POLAR STAR OPTIMA (BMG Lab technologies). Cell
Growth Inhibition was normalized to the controls.
Soft-agar colony formation of patient tumor-derived
xenograft cells
P7170 was evaluated at log concentrations from 0.01 nM
to 1 μM in a 14-day soft agar colony formation assay. The
Patient tumor explants are passaged as subcutaneous
xenograft in NMRI nu/nu mice. For the clonogenic assay,
cells were isolated from tumor xenografts (also referred
to as patient derived tumor xenografts, PDX) of 13 NSCLC
patient specimens established in mice under sterile condi-
tions followed by mechanical disaggregation and subse-
quent incubation with an enzyme cocktail [consisting of
collagenase type IV (41 U /ml), DNase I (125 U /ml), hyal-
uronidase type III (100 U /ml) and dispase II (1.0 U /ml) in
RPMI 1640 medium] at 37°C for 45 minutes. Cells were
allowed to pass through sieves of 200 μm and 50 μm sterile
nylon mesh and washed twice with sterile PBS buffer. The
percentage of viable cells is determined in Neubauer
Hemocytometer using trypan blue exclusion. The bottom
layer consisted of 0.2 ml/well Iscove’s Modified Dulbecco’s
Medium (Invitrogen), supplemented with 20% (v/v) fetal
calf serum (Sigma), 0.01% (w/v) gentamicin (Invitrogen)
and 0.75% (w/v) agar (BD Biosciences). Tumor cells were
added to 0.2 ml of the same culture medium supplemented
with 0.4% (w/v) agar and plated in 24-multiwell dishes
onto the bottom layer. P7170 at desired concentration in
0.2 ml culture medium was overlaid on the bottom layer.
Every dish included six untreated control wells and drug
treated groups in triplicate at 6 concentrations. Cultures
were incubated at 37°C and 7.5% CO2 in the humidified
atmosphere for up to 20 days and monitored closely for
colony growth using an inverted microscope. Within this
period, in vitro tumor growth leads to the formation of
colonies with diameter > 50 μm. At the time of maximum
colony formation, counts were performed with an auto-
mated image analysis system (OMNICON 3600, Biosys
GmbH). 24 h prior to evaluation, vital colonies are stained
with a sterile aqueous solution of 2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-phenyltetrazolium chloride (1 mg/ml, 100
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[(conc. Of inhibitor) versus response (%T/C)] using Oncotest
in house database system) or nonlinear regression [log (conc.
of inhibitor)] versus response (% T/C) using Graph pad Prism
5 for windows, version 5.01, Graph pad software Inc. CA). For
calculation of mean IC50 values the geometric mean is used.
Results are presented as mean graph plots or heat maps
(individual IC50 values relative to the geometric mean IC50
value) over all cell lines as tested.
Immunoblotting
Whole cell extracts from treated cell lines or xenografts
were prepared using cell lysis buffer [a mixture of protease
inhibitor cocktail (Sigma, Cat #P8340) and phosphatase
inhibitors (40 mM Beta-glycerol phosphate (Sigma, Cat
#G9422), 4 mM DTT (MP Biomedicals, Cat #194821),
0.4 mM NaF (Sigma Cat #S1504), 0.4 mM Sodium-
orthovanadate (Sigma, Cat #S6508)]. Total protein con-
centration from the soluble fraction was determined by
Bradford’s method. Equal amount of total protein was
resolved on SDS-PAGE gels; protein bands were electro-
transferred onto PVDF membrane. Antibodies for im-
munoblotting are from Cell Signaling Technology [pAKT
(S473) (#9271); AKT (#9272); pS6 (S235/236) (#2211); S6
(#2217); p4EBp1 (T37/46) (#9459); pERK (T202/Y204)
(#9101); ERK (#4695)]; and from Sigma (Actin #A2228).
SuperSignal West Femto (Thermo Scientific Cat #34096)
was used for chemiluminescence detection and the signals
were captured in the ChemiDoc XRS image system (Bio-
Rad). The protein western band intensities were calculated
using NIH Image-J software.
Immunofluorescence
pS6 and p4EBP1 staining
H460 cells were seeded in 96-well Black/clear plates
(Nunc) followed by treatment on the next day with
P7170 for 1 h. Cells were fixed with 3.7% PFA in 1× PBS
at RT for 20 min, cell membranes permeabilized with
0.1% Triton X-100 for 90 sec, followed by blocking with
5% BSA (Sigma-Aldrich Cat #A7030) (w/v) in 1 × PBS
for 2 h before immunostaining. Primary antibodies used
were pS6 and p4EBP1 (Cell Signaling) at dilution (1:500)
at RT for 1 h. Secondary Goat Anti-Rabbit antibody IgG
(H + L) DyLight 549 Thermo Scientific Cat #35557)
probed at 1:1000 dilution for 1 h. Nuclei were stained with
Hoechst 33342 (AnaSpec Inc. Cat #83218). Plates were
scanned on Cellomics Array Scan VTI HCS Reader.
pSTAT3 staining
Exponentially growing A549 cells were seeded on cover-
slips in a 24 well plate (Nunc) in complete growth media
for 14-16 h followed by culture in no serum media for
another 16-20 h. Serum starved cells were treated with
P7170 (0.1-1 μM) for 1 h followed by stimulation with30 ng/ml rhIL-6 (R&D systems Cat. No. 206-IL) for
20 min. Cells were washed with 1× PBS, fixed and
permeabilized as described earlier. Primary antibodies
used were pSTAT3(Y705) (Cell Signaling Cat #9131) incu-
bated (1:100 dilution) at RT for 1 h. Secondary antibody
and nuclear staining performed as earlier. Cell images
were captured by confocal microscopy (Leica, LSM700)
with ZEN2009 software.Annexin V – FITC staining and flow cytometry
Exponentially growing H460 cells were seeded in 6 well
plate, treated 16 h later with P7170 at 0.3 μM for 24 h.
Cells were harvested by trypsinization and processed for
FITC Annexin V staining as per manufacture’s protocol
(BD Pharmingen Cat #556420). The samples were acquired
by FACSCalibur flow cytometer and the signal inten-
sities were analyzed using CellQuest Pro software (Becton
Dickinson).STAT3 luciferase assay
STAT3 Reporter HeLa cells were seeded (2 × 104 cells/well)
in a 96- well white plate (Nunclon Cat #167008). After
16 h, cells were treated for 1 h with P7170 followed by
stimulation with 100 ng/ml Oncostatin M (Calbiochem
Cat #496260) for 7 h. Cells were lysed in a buffer (a mix-
ture of 125 mM Tris phosphate buffer, 10 mM EDTA,
10 mM DTT, 50% glycerol, 5% Triton ×100) before the
addition of luciferin (Promega Cat #E160E), ATP (Sigma
Cat #A2383), and coenzyme A (Sigma Cat #C3019). The
luminescence generated was measured using POLARstar
OPTIMA (BMG Lab technologies). Cytotoxicity due to
drug treatment (total 8 h) was determined using propidium
iodide.In vivo xenograft models of NSCLC cell lines and treatment
Nude mice (male, ~6 wks.) from Harlan Labs were housed
in animal isolators (Harlan Inc.) with 12 h light dark cycle,
55-75% relative humidity at 22-25°C of room temperature,
given access to autoclaved rodent diet (National Centre
for Laboratory Animal Sciences, Hyderabad, India) and
water ad libitum. Animals were acclimatized for a week
before implanting subcutaneously with 5×106 NSCLC
cells (0.2 ml/site with BD matrigel) in the right flank.
When the mean xenograft size reached ~100 mm3, mice
were randomized into the study groups (n = 9/group).
P7170 was suspended in 0.25% CMC +0.1% Tween-80
for administering via oral (p.o.) route. Animal body
weight and physical signs were monitored throughout
the experiment every day. The tumor size was measured
with calipers 2-3 times/wk. and the tumor volumes
were calculated using the following formula: (length ×
width)2 × 0.5.
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PK analyses
Plasma samples or tumor homogenates were processed
to extract P7170 followed by determining P7170 concen-
trations using LC-MS/MS.
Tumor homogenate preparation
Tumor samples were diluted 4 times of its weight with
homogenization solvent methanol: saline (75:25 v/v) and
then homogenized to obtain tissue extracts until a uni-
form homogenate was obtained.
Sample preparation
An aliquot (100 μL) of plasma or tumor homogenate
was spiked individually with 10 μL of internal standard
(P6569, a compound structurally similar to P7170,
1.0 μg/mL). The samples were vortexed for 10 seconds
followed by addition of 1 mL ethyl acetate and further
vortexed for 5 min. The samples were then centrifuged
at 10000 rpm for 5 minutes at 4°C. Supernatants (800 μL)
were transferred to relabeled glass tubes and its solvent
portion was allowed to evaporate under nitrogen. The dried
residues were reconstituted using 200 μL acetonitrile: water
(90:10 v/v) by vortex and centrifuged. The supernatants
were analyzed for P7170 by a fit-for-purpose LC-MS/MS
method. Pharmacokinetic analyses were carried out at each
dose level using the non-compartmental analysis tool of
Phoenix WinNonlin software (Version 6.1).
LC-MS/MS analysis
The chromatographic LC-MS/MS system consisted a
Shimadzu LC pump with an API 4000 triple mass spec-
trometer (Applied Biosystems/MDS Sciex, Foster City,
CA) fitted with a TurboIon- Spray interface. P7170 and
P6569 (internal standard) were separated on a Thermo
BDS Hypersil C18 column of 100 × 4.6 mm I.D. and
particle size of 5 μ. The mobile phase composed of two
solvents: Solvent A, 5 mM Ammonium formate in 0.1%
formic acid and the Solvent B, Acetonitrile in a ratio of
20:80% v/v, respectively. The isocratic HPLC condition
was used for analysis. The samples were introduced into
the HPLC column with a SIL-20 AC XR autosampler
(Shimadzu) and an integrated HPLC pumping system
(Shimadzu LC-20 AD XR) with 5 μL injection volume at
a flow rate of 0.8 mL/min for a 3 min run time. The ana-
lytes were then eluted at RT 1.45 and 1.50 min for
P7170 and P6569, respectively followed by MS detection.
Electro-spray ionization in positive ion mode (ESI+) was
used for ionization and multiple reaction monitor
(MRM) mode was chosen for detection. The precursor-
product ions pairs were m/z 528.0→ 461.4 (for P7170),
and m/z 504.3→ 437.2 (for internal standard, P6569).
The optimized acquisition parameters were: Temperature
set at 400°C; Curtain gas (CUR), 30 psi (99.99% Nitrogen);Nebulizer Gas (Gas 1), 60 psi (99.99% Nitrogen); Heater
Gas (Gas 2), 50 psi (99.99% Nitrogen); Collision-Activated
Dissociation (CAD) Gas: 10 v; Ion Spray Voltage (IS),
5500 v.
The unknown plasma and tumor concentrations of
P7170 (unbound and plasma protein bound) were calcu-
lated from the calibration standards at 0 to 15000 ng/mL
by spiking 10 × standards in blank plasma and tumor
homogenates collected from untreated nude mice using
linear regression according to the following equation:
y ¼ axþ b
Where,
y = Peak area ratio of analyte: internal standard
b = Intercept of the corresponding standard curve
a = Slope of the standard curve
x = Concentration of analyte (ng/mL)
Pharmacokinetic analysis was carried out at each dose
level using the non-compartmental analysis tool of Win-
Nonlin Professional version 6.1. Pharmacokinetic param-
eters were determined from mean plasma and tumor
concentrations thus obtained at each time point by non-
compartmental analysis using Phoenix WinNonlin Pro-
fessional version 6.1. Concentrations below limit of
quantification (LLOQ = 0.5 ng/mL) were considered as
zero for PK analysis. Nominal time points were used
for PK analysis.
PK-PD analyses
PD analysis was performed to derive a correlation between
tumor marker levels (pS6, pAKT and p4EBP1) and the
corresponding plasma and tumor P7170 concentrations
after dosing the tumor-bearing mice with P7170 once
daily for 3 days. Plasma and tumors samples were col-
lected at 1, 4, 8, 24 h post-P7170-last dose for estimating
P7170 concentrations by LC-MS/MS. P7170 tumor con-
centrations for each dose (1, 5, 10, or 20 mg/kg) were cal-
culated based on the AUC (area under curve) constructed
using concentrations at 1, 4, 8, 24 h post-P7170-last dose.
The normalized phosphoprotein western band intensities
of AKT (S473), S6 (S235/236), and 4EBP1 (T37/46) as
determined in tumor xenografts (in 1, 4, 8, 24 h post
P7170-last dose) of different experimental arms were plot-
ted against corresponding tumor xenograft P7170 concen-
tration using the non-compartmental analysis tool using
Phoenix WinNonlin Professional version 6.1. The analyses
were performed using various inhibitory Emax models
available in Phoenix WinNonlin software (version 6.1).
The model with the lowest AIC (Akaike Information
Criteria) value is selected as the best fit model. If two
models had similar AIC values, then selection was
made qualitatively by visual inspection of the model fit
and % CV of the parameter estimates.
Venkatesha et al. Molecular Cancer 2014, 13:259 Page 10 of 11
http://www.molecular-cancer.com/content/13/1/259Additional files
Additional file 1: Figure S1. P7170 inhibited PI3K-mTOR signaling.
pS6 (S235/236) and p4EBP1 (T37/46) protein levels were determined by
immunofluorescence staining in H460 cells. H460 cells were seeded in 96-well
plates (black and transparent bottom) before treatment with 0.1 or 1 μM of
P7170 for 1 h; drug containing media was removed and the cells were fixed
and stained with antibodies to phosphorylated form of human S6 and 4EBP1
proteins and secondary antibodies conjugated to DyLight 549, and signals
acquired and analyzed in Cellomics high content array scan reader.
Additional file 2: Figure S2. P7170 inhibits the colony formation of
tumor cells isolated from Non Small Cell Lung Cancer patients. Dose
response curves for various patient tumor xenograft-derived NSCLC cells
treated with P7170 in a soft-agar colony formation assay.
Additional file 3: Figure S3. Cellular apoptotic analysis after P7170
treatment. In the flow cytometry analysis gating was set using untreated
cells (A); Increased cellular apoptosis and necrosis after P7170 treatment
(B) or Paclitaxel treatment (C).
Additional file 4: Figure S4. Body weight changes of nude mice bearing
NSCLC cell line-derived xenografts treated with P7170. (A) Percent body
weight changes in the H1650 NSCLC cell-derived xenograft treated with
P7170 (see Table 2); (B) Percent body weight changes in the H1975 NSCLC
cell-derived xenograft treated with P7170 (see Table 2); Percent body weight
changes in the H460 NSCLC cell-derived xenograft treated with P7170
(see Figure 3A).
Additional file 5: Table S1. Summary of PK/PD study. Correlation analysis
of tumor volume to P7170 concentration. E0 represents the level of biomarker
in plasma and tumor at baseline i.e. when the concentration of drug in
plasma and tumor is 0 (zero). IC50 represents the concentration of drug in
plasma and tumor required to produce 50% of the maximal inhibition.
Additional file 6: Figure S5. Pharmacodynamic correlation of pAKT (S473)
and p4EBP1 (T37/46) with tumor P7170 concentrations. Based on the study
described in Figure 3, pharmacodynamic correlations of tumor pAKT (S473)
and p4EBP1 (T37/46) levels to the plasma and tumor concentrations of
P7170 were performed. The correlation plots calculated using the model
(Additional file 5: Table S1): Correlation of tumor pAKT levels with P7170
concentrations in plasma (A) and tumor (B); and correlation of tumor
p4EBP1 levels with P7170 concentrations in plasma (C) and tumor (D).
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